Amneal expands India operations after Kashiv buy, builds biosimilars portfolio
The US drugmaker is building on Kashiv BioSciences' biologics capabilities to expand its India play across biosimilars, complex medicines, manufacturing and R&D.
Attribution
This digest is published with acknowledgment to Business Today. For the complete analysis, headnotes, and citations, please refer to the source.
Read on Business Today